Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Axon Regeneration After Brain or Spinal Cord Injury

Posted Nov 20 2012 7:00pm

Description of Invention:
The invention is directed to modification of a particular sugar by the enzyme arylsulfatase B (ARSB), which results in axon regeneration.

Following traumatic brain or spinal cord injury, glial scars prevent regeneration of axons. Chondroitin sulfate proteoglycans (CSPGs) are major components of glial scars. CSPGs are made of a protein core containing glycosaminoglycan (GAG) sugar side chains, which, when sulfated, are responsible for the inhibitory activity of glial scars. Specifically, NIH researchers have shown that the 4-sulfate unit on a certain sugar on GAG is responsible for inhibiting axon regrowth and, when the 4-sulfate unit is reduced, axon regrowth is observed. Moreover, removal of this 4-sulfate unit by the ARSB enzyme promotes axon regrowth.

As a potential therapy for spinal cord injuries, researchers developed a vector expressing ARSB and demonstrated that this vector promotes axon regeneration when injected into the spinal cord of a mouse.

Applications:
  • Treatment of brain and spinal cord injury
  • Treatment of other CNS injuries, including stroke
  • Treatment of heart attack


Advantages:
  • There are no existing products for treatment of traumatic spinal cord injury
  • ARSB is already approved for treatment of Mucopolysaccharoidosis VI, a lysosomal storage disease


Development Status:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)


Inventors:
Herbert M Geller (NHLBI)
Yasuhiro Katagiri (NHLBI)


Patent Status:
HHS, Reference No. E-214-2012/0
US, Application No. 61/705,555 filed 25 Sep 2012


Relevant Publication:
  1. Wang H, et al. [ PMID 18768934 ]


Collaborative Research Opportunity:
The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of ARSB in axonal regeneration after brain or spinal cord injury using animal models. For collaboration opportunities, please contact Denise Crooks, Ph.D. at 301-435-0103 or crooksd@mail.nih.gov .


For Licensing Information Please Contact:
Lauren Nguyen-Antczak Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: nguyenantczakla@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 2502

Updated: 11/2012

Post a comment
Write a comment: